Metformin protects against cisplatin-induced tubular cell apoptosis and acute kidney injury via AMPKα-regulated autophagy induction

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Li, Jianzhong ^a   Gui, Yuan ^a   Ren, Jiafa ^a   Liu, Xin ^a   Feng, Ye ^a   Zeng, Zhifeng ^a   He, Weichun ^a   Yang, Junwei ^a   Dai, Chunsun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMPK ALPHA1 SUBUNIT, MOUSE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; PROTECTIVE AGENT;

ACUTE KIDNEY INJURY; ANIMAL; APOPTOSIS; AUTOPHAGY; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MOUSE; PHOSPHORYLATION; RAT; RNA INTERFERENCE; WESTERN BLOTTING;

ACUTE KIDNEY INJURY; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; CELL LINE; CISPLATIN; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; MALE; METFORMIN; MICE; MICROSCOPY, FLUORESCENCE; PHOSPHORYLATION; PROTECTIVE AGENTS; RATS; RNA INTERFERENCE;

EID: 84964050119     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23975     Document Type: Article

References (50)

1. Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-79 (2003)
2. Lameire, N. H. et al. Acute kidney injury: an increasing global concern. Lancet 382, 170-9 (2013)
3. Sanchez-Gonzalez, P. D., Lopez-Hernandez, F. J., Lopez-Novoa, J. M., & Morales, A. I. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit Rev Toxicol. 41, 803-21 (2011)
4. Bonegio, R., & Lieberthal, W. Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens 11, 301-8 (2002)
5. Pabla, N., & Dong, Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73, 994-1007 (2008)
6. Gabbiani, C., Magherini, F., Modesti, A., & Messori, L. Proteomic and metallomic strategies for understanding the mode of action of anticancer metallodrugs. Anticancer Agents Med Chem. 10, 324-37 (2010)
7. Mizushima, N., Ohsumi, Y., & Yoshimori, T. Autophagosome formation in mammalian cells. Cell Struct Funct 27, 421-9 (2002)
8. Periyasamy-Thandavan, S. et al. Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int 74, 631-40 (2008)
9. Jiang, M., Liu, K., Luo, J., & Dong, Z. Autophagy is a renoprotective mechanism during in vitro hypoxia and in vivo ischemiareperfusion injury. Am J Pathol. 176, 1181-92 (2010)
10. Liu, S. et al. Autophagy plays a critical role in kidney tubule maintenance, aging and ischemia-reperfusion injury. Autophagy 8, 826-37 (2012)
11. Kimura, T. et al. Autophagy protects the proximal tubule from degeneration and acute ischemic injury. J Am Soc Nephrol. 22, 902-13 (2011)
12. Takahashi, A. et al. Autophagy guards against cisplatin-induced acute kidney injury. Am J Pathol. 180, 517-25 (2012)
13. Jiang, M. et al. Autophagy in proximal tubules protects against acute kidney injury. Kidney Int 82, 1271-83 (2012)
14. Li, J. et al. Rictor mTORC2 protects against cisplatin-induced tubular cell death and acute kidney injury. Kidney Int 86, 86-102 (2014)
15. Yamahara, K. et al. Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions. J Am Soc Nephrol. 24, 1769-81 (2013)
16. Grahammer, F. et al. mTORC1 maintains renal tubular homeostasis and is essential in response to ischemic stress. Proc Natl Acad Sci USA 111, E2817-26 (2014)
17. Li, L., Wang, Z. V., Hill, J. A., & Lin, F. New autophagy reporter mice reveal dynamics of proximal tubular autophagy. J Am Soc Nephrol 25, 305-15 (2014)
18. Hardie, D. G. AMPK: positive and negative regulation, and its role in whole-body energy homeostasis. Curr Opin Cell Biol. 33, 1-7 (2015)
19. Mihaylova, M. M., & Shaw, R. J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 13, 1016-23 (2011)
20. Miller, R. A., & Birnbaum, M. J. An energetic tale of AMPK-independent effects of metformin. J Clin Invest 120, 2267-70 (2010)
21. Ouyang, J., Parakhia, R. A., & Ochs, R. S. Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem. 286, 1-11 (2011)
22. Tripathi, D. N. et al. Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1. Proc Natl Acad Sci USA 110, E2950-7 (2013)
23. Hardie, D. G., Ross, F. A., & Hawley, S. A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13, 251-62 (2012)
24. Decleves, A. E., Sharma, K., & Satriano, J. Beneficial Effects of AMP-Activated Protein Kinase Agonists in Kidney Ischemia- Reperfusion: Autophagy and Cellular Stress Markers. Nephron Exp Nephrol. (2014)
25. He, L. et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137, 635-46 (2009)
26. Stratton, I. M. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321, 405-12 (2000)
27. Viollet, B. et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 122, 253-70 (2012)
28. Giovannucci, E. et al. Diabetes and cancer: a consensus report. Diabetes Care 33, 1674-85 (2010)
29. Libby, G. et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32, 1620-5 (2009)
30. Schneider, M. B. et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120, 1263-70 (2001)
31. Ohno, T. et al. Metformin suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-+ Leprdb/+ Leprdb mice. Plos One 10, e0124081 (2015)
32. Chen, H. P. et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62, 606-15 (2013)
33. Zhou, G. et al. Role of AMP-Activated protein kinase in mechanism of metformin action. J Clin Invest 108, 1167-74 (2001)
34. Dowling, R. J., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. Metformin inhibits mammalian target of rapamycindependent translation initiation in breast cancer cells. Cancer Res 67, 10804-12 (2007)
35. Mao-Ying, Q. L. et al. The anti-diabetic drug metformin protects against chemotherapy-induced peripheral neuropathy in a mouse model. Plos One 9, e100701 (2014)
36. Janjetovic, K. et al. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol. 651, 41-50 (2011)
37. Morales, A. I. et al. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int 77, 861-9 (2010)
38. Sahu, B. D., Kuncha, M., Putcha, U. K., & Sistla, R. Effect of metformin against cisplatin induced acute renal injury in rats: a biochemical and histoarchitectural evaluation. Exp Toxicol Pathol. 65, 933-40 (2013)
39. Kaushal, G. P., Kaushal, V., Hong, X., & Shah, S. V. Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int 60, 1726-36 (2001)
40. Kinsey, G. R., Li, L., & Okusa, M. D. Inflammation in acute kidney injury. Nephron Exp Nephrol. 109, e102-7 (2008)
41. Calixto, M. C. et al. Metformin attenuates the exacerbation of the allergic eosinophilic inflammation in high fat-diet-induced obesity in mice. Plos One 8, e76786 (2013)
42. He, L., Livingston, M. J., & Dong, Z. Autophagy in acute kidney injury and repair. Nephron Clin Pract. 127, 56-60 (2014)
43. Wu, Y. T. et al. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem. 285, 10850-61 (2010)
44. Xie, Z. et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 60, 1770-8 (2011)
45. Kordes, S. et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 16, 839-47 (2015)
46. Greenhill, C. Gastric cancer. Metformin improves survival and recurrence rate in patients with diabetes and gastric cancer. Nat Rev Gastroenterol Hepatol. 12, 124 (2015)
47. Lin, J. J. et al. Survival of patients with stage IV lung cancer with diabetes treated with metformin. Am J Respir Crit Care Med. 191, 448-54 (2015)
48. Margel, D. et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol. 31, 3069-75 (2013)
49. Lin, C. C. et al. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-Activated protein kinase pathway. Am J Respir Cell Mol Biol. 49, 241-50 (2013)
50. Rattan, R., Graham, R. P., Maguire, J. L., Giri, S., & Shridhar, V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 13, 483-91 (2011)